CytomX Therapeutics Statistics
Share Statistics
CytomX Therapeutics has 78.26M shares outstanding. The number of shares has increased by 15.56% in one year.
| Shares Outstanding | 78.26M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.18% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 76.94M |
| Failed to Deliver (FTD) Shares | 35.48K |
| FTD / Avg. Volume | 2.77% |
Short Selling Information
The latest short interest is 5.54M, so 7.08% of the outstanding shares have been sold short.
| Short Interest | 5.54M |
| Short % of Shares Out | 7.08% |
| Short % of Float | 7.2% |
| Short Ratio (days to cover) | 3.52 |
Valuation Ratios
The PE ratio is -201.06 and the forward PE ratio is -1.79.
| PE Ratio | -201.06 |
| Forward PE | -1.79 |
| PS Ratio | 1.13 |
| Forward PS | 1.7 |
| PB Ratio | -2.41 |
| P/FCF Ratio | -2.01 |
| PEG Ratio | n/a |
Enterprise Valuation
CytomX Therapeutics Inc. has an Enterprise Value (EV) of 111.21M.
| EV / Earnings | -195.44 |
| EV / Sales | 1.1 |
| EV / EBITDA | -25.81 |
| EV / EBIT | -17.15 |
| EV / FCF | -1.96 |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.
| Current Ratio | 1.17 |
| Quick Ratio | 1.17 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.01% and return on capital (ROIC) is -3.32%.
| Return on Equity (ROE) | 0.01% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | -3.32% |
| Revenue Per Employee | 843.45K |
| Profits Per Employee | -4.74K |
| Employee Count | 120 |
| Asset Turnover | 0.5 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 3.89M |
| Effective Tax Rate | 1.17 |
Stock Price Statistics
The stock price has increased by -49.1% in the last 52 weeks. The beta is 1.06, so CytomX Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.06 |
| 52-Week Price Change | -49.1% |
| 50-Day Moving Average | 1.05 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 33.35 |
| Average Volume (20 Days) | 1.28M |
Income Statement
In the last 12 months, CytomX Therapeutics had revenue of 101.21M and earned -569.00K in profits. Earnings per share was -0.01.
| Revenue | 101.21M |
| Gross Profit | 101.21M |
| Operating Income | -6.48M |
| Net Income | -569.00K |
| EBITDA | -4.31M |
| EBIT | -6.48M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 17.17M in cash and 13.97M in debt, giving a net cash position of 3.20M.
| Cash & Cash Equivalents | 17.17M |
| Total Debt | 13.97M |
| Net Cash | 3.20M |
| Retained Earnings | -723.45M |
| Total Assets | 138.98M |
| Working Capital | 4.95M |
Cash Flow
In the last 12 months, operating cash flow was -56.03M and capital expenditures -840.00K, giving a free cash flow of -56.88M.
| Operating Cash Flow | -56.03M |
| Capital Expenditures | -840.00K |
| Free Cash Flow | -56.88M |
| FCF Per Share | -0.77 |
Margins
Gross margin is 100%, with operating and profit margins of -6.41% and -0.56%.
| Gross Margin | 100% |
| Operating Margin | -6.41% |
| Pretax Margin | 3.28% |
| Profit Margin | -0.56% |
| EBITDA Margin | -4.26% |
| EBIT Margin | -6.41% |
| FCF Margin | -56.19% |
Dividends & Yields
CTMX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.18% |
| FCF Yield | -85.49% |
Analyst Forecast
The average price target for CTMX is $5.79, which is 581.2% higher than the current price. The consensus rating is "Hold".
| Price Target | $5.79 |
| Price Target Difference | 581.2% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -5.72 |
| Piotroski F-Score | 5 |